# Dasotraline Adult ADHD Study

> **NCT02276209** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 636 (actual)

## Conditions studied

- Adult Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Dasotraline
- **DRUG:** Dasotraline
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02276209
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 636 (ACTUAL)
- **Last updated:** 2017-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02276209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02276209, "Dasotraline Adult ADHD Study". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02276209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*